William Anthony Vernon net worth and biography

William Vernon Biography and Net Worth

Director of NovoCure

Tony Vernon has been a director of Novocure since 2006, serving on our compensation committee since 2012 and as chairperson of our nominating and corporate governance committee since 2015. Mr. Vernon served as the Chief Executive Officer of the Kraft Foods Group, a food products company, from 2012 to 2014 and served as a senior advisor through May 2015. From 2009 to 2011, Mr. Vernon served as the President of Kraft Foods North America and as an Executive Vice President of Kraft Foods. From 2006 to 2009, Mr. Vernon served as the healthcare industry partner for Ripplewood Holdings, a private equity firm. From 1982 to 2005, Mr. Vernon worked for Johnson & Johnson in a variety of leadership roles, including as Company Group Chairman of DePuy Orthopaedics, President of Centocor Biologics, President of McNeil Consumer Products and Nutritionals, and President of The Johnson & Johnson-Merck Joint Venture. Mr. Vernon currently serves on the boards of Intersect ENT Inc. and The WhiteWave Foods Company, and he previously served on the board of the Kraft Foods Group from 2012 to 2015. Mr. Vernon holds a B.A. in history from Lawrence University and an M.B.A. from Northwestern University’s Kellogg School of Management.

What is William Anthony Vernon's net worth?: The estimated net worth of William Anthony Vernon is at least $3.13 million as of June 4th, 2024. Mr. Vernon owns 164,833 shares of NovoCure stock worth more than $3,126,882 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Vernon may own. Learn More about William Anthony Vernon's net worth.
How do I contact William Anthony Vernon?: The corporate mailing address for Mr. Vernon and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at investorinfo@novocure.com. Learn More on William Anthony Vernon's contact information.
Has William Anthony Vernon been buying or selling shares of NovoCure?: William Anthony Vernon has not been actively trading shares of NovoCure within the last three months. Most recently, W Anthony Vernon sold 964 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $23.89, for a transaction totalling $23,029.96. Following the completion of the sale, the director now directly owns 164,833 shares of the company's stock, valued at $3,937,860.37. Learn More on William Anthony Vernon's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 5 times. They sold a total of 3,220 shares worth more than $61,749.10. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

William Anthony Vernon Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2024	Sell	964	$23.89	$23,029.96	164,833

William Anthony Vernon Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $18.97

$18.31

$19.06

50 Day Range

MA: $21.87

$18.19

$27.02

2 Week Range

Now: $18.97

$11.70

$34.13

Volume

490,446 shs

Average Volume

1,191,815 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63